• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

IntraLens Vision changes name, revises strategy

Article

Lake Forest, CA—IntraLens Vision Inc. has changed its name to ReVision Optics Inc. (RVO) to align with its strategy to enter the presbyopia market.

Lake Forest, CA-IntraLens Vision Inc. has changed its name to ReVision Optics Inc. (RVO) to align with its strategy to enter the presbyopia market.

"We feel our new name, ReVision Optics, perfectly suits both our corporate mission and our products," said J. Randy Alex-ander, ReVision Optics president. "ReVision Optics will be targeting the refractive surgery market with an emphasis on the surgical correction of presbyopia via an intracorneal lens."

Alexander added that IntraLase Corp. has agreed to develop specialized software that will enable ReVision Optics to develop the collateral products to move forward in the marketplace. The software will enable ReVision Optics to produce two types of customized flaps that will assist eye surgeons to easily inject the company's intracorneal lenses.

"While continuing to gain global market share of corneal flaps for LASIK, an integral part of our strategy is to also establish our laser as enabling technology for corneal applications, which include corneal inlays, rings, and therapeutic procedures," said Robert J. Palmisano, IntraLase president and chief executive officer.

As part of this agreement with ReVision, IntraLase will acquire full rights to the name IntraLens.

ReVision Optics will develop, manufacture, and market intracorneal lenses to correct and maintain vision. Its lenses are made from its proprietary microporous hydrogel material and will be trademarked under the name PresbyLens.

Related Videos
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.